Literature DB >> 12209498

Choosing treatment for proliferative lupus nephritis.

James E Balow.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12209498     DOI： 10.1002/art.10466

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  4 in total

1.  Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona.

Authors:  Mehul P Dixit; Erika Bracamonte; Naznin Dixit
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

2.  Justice and health care in the rheumatic diseases.

Authors:  C Ronald MacKenzie; Franklin G Miller; Joseph J Fins
Journal:  HSS J       Date:  2005-09

3.  Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study.

Authors:  Hanns-Martin Lorenz; Wilhelm H Schmitt; Vladimir Tesar; Ulf Müller-Ladner; Ingo Tarner; Ingeborg A Hauser; Falk Hiepe; Tobias Alexander; Heike Woehling; Kyuichi Nemoto; Peter A Heinzel
Journal:  Arthritis Res Ther       Date:  2011-03-01       Impact factor: 5.156

4.  Variability of the impact of adverse events on physicians' decision making.

Authors:  Raluca Cozmuta; Peter A Merkel; Elizabeth Wahl; Liana Fraenkel
Journal:  BMC Med Inform Decis Mak       Date:  2014-09-25       Impact factor: 2.796
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.